#1 Clinical Trials Search in Europe

Lbl-007

This article summarizes several clinical trials investigating the use of LBL-007, a novel immunotherapy drug, in treating various advanced cancers. LBL-007 is being studied alone and in combination with other cancer treatments to evaluate its safety and effectiveness against solid tumors and blood cancers. The trials aim to determine optimal dosing, assess side effects, and measure how well LBL-007 works to shrink tumors and improve survival in patients with difficult-to-treat cancers.

Table of Contents

What is LBL-007?

LBL-007 is an investigational drug being studied for the treatment of various types of cancer. It is classified as an immunotherapy, which means it works by helping your body’s immune system fight cancer cells. Specifically, LBL-007 is a type of drug called an anti-LAG-3 antibody. LAG-3 stands for Lymphocyte Activation Gene-3, which is a protein found on certain immune cells[1].

How Does LBL-007 Work?

LBL-007 works by targeting and blocking the LAG-3 protein on immune cells. When LAG-3 is active, it can prevent immune cells from effectively fighting cancer. By blocking LAG-3, LBL-007 helps to “take the brakes off” the immune system, allowing it to better recognize and attack cancer cells[1].

This mechanism of action is similar to other immunotherapy drugs that target proteins like PD-1 and CTLA-4. By combining LBL-007 with other immunotherapy drugs, researchers hope to enhance the overall immune response against cancer[2].

Cancers Treated with LBL-007

LBL-007 is being studied in clinical trials for various types of cancer, including:

  • Advanced solid tumors: This term refers to cancers that form solid masses in the body and have spread or are in an advanced stage[3].
  • Colorectal cancer: Cancer that starts in the colon or rectum[4].
  • Melanoma: A type of skin cancer[5].
  • Esophageal squamous cell carcinoma: Cancer that forms in the flat cells lining the esophagus[6].
  • Non-small cell lung cancer (NSCLC): The most common type of lung cancer[7].
  • Head and neck squamous cell carcinoma: Cancer that begins in the flat cells that line the inside of the mouth, nose, and throat[8].

Combination Therapies

LBL-007 is often studied in combination with other cancer treatments to potentially enhance its effectiveness. Some common combinations include:

  • LBL-007 + Tislelizumab: Tislelizumab is another immunotherapy drug that targets a protein called PD-1[2].
  • LBL-007 + Tislelizumab + Chemotherapy: This combination adds traditional chemotherapy drugs to the immunotherapy approach[9].
  • LBL-007 + Toripalimab: Toripalimab is also an anti-PD-1 immunotherapy drug[3].
  • LBL-007 + Tislelizumab + Bevacizumab: Bevacizumab is a drug that targets blood vessel growth in tumors[4].

Clinical Trials and Research

LBL-007 is currently being studied in various phases of clinical trials. These trials are designed to evaluate the drug’s safety, effectiveness, and optimal dosing. Some key aspects of the ongoing research include:

  • Phase 1 studies: These early studies focus on finding the right dose and assessing initial safety[5].
  • Phase 2 studies: These trials further evaluate the drug’s effectiveness and continue to monitor safety in larger groups of patients[6].
  • Combination studies: Many trials are exploring how LBL-007 works when combined with other cancer treatments[7].
  • Biomarker research: Some studies are looking at specific markers in patients’ tumors or blood to help predict who might benefit most from LBL-007[3].

Potential Side Effects

As LBL-007 is still in clinical trials, the full range of potential side effects is not yet known. However, based on similar immunotherapy drugs, some possible side effects may include:

  • Fatigue: Feeling very tired or weak.
  • Skin reactions: Rash, itching, or changes in skin color.
  • Gastrointestinal issues: Diarrhea, nausea, or loss of appetite.
  • Immune-related side effects: Because LBL-007 affects the immune system, it can sometimes cause the immune system to attack healthy parts of the body. This can lead to inflammation in various organs[10].

It’s important to note that not everyone experiences these side effects, and many can be managed with proper medical care. Patients in clinical trials are closely monitored for any adverse reactions.

Aspect Details
Drug Name LBL-007
Drug Type Immunotherapy targeting LAG-3
Administration Intravenous infusion
Cancer Types Studied Advanced solid tumors, melanoma, colorectal cancer, non-small cell lung cancer, head and neck cancer, esophageal cancer
Combination Therapies Tislelizumab (anti-PD-1), chemotherapy, bevacizumab
Primary Outcomes Safety, maximum tolerated dose, objective response rate
Secondary Outcomes Progression-free survival, overall survival, duration of response, pharmacokinetics
Trial Phases Phase 1, Phase 1b/2, Phase 2

FAQ

  • What is LBL-007? LBL-007 is an investigational immunotherapy drug that targets LAG-3, a protein involved in regulating immune responses. It is being studied as a potential treatment for various advanced cancers, often in combination with other immunotherapy drugs or standard chemotherapy.
  • What types of cancer is LBL-007 being tested for? Clinical trials are evaluating LBL-007 for several cancer types, including advanced solid tumors, melanoma, colorectal cancer, non-small cell lung cancer, head and neck cancer, and esophageal cancer.
  • How is LBL-007 given to patients? LBL-007 is administered as an intravenous (IV) infusion, typically every 2-3 weeks. The exact dosing schedule varies between trials and may be combined with other IV medications.
  • What are the main goals of these clinical trials? The primary goals are to evaluate the safety of LBL-007, determine the best dose to use, and assess how effective it is at shrinking tumors and improving survival. Researchers are measuring outcomes like tumor response rates, progression-free survival, and overall survival.
  • Are there any known side effects of LBL-007? As LBL-007 is still in clinical trials, the full side effect profile is not yet known. The studies are closely monitoring patients for any adverse events. Common side effects of similar immunotherapy drugs can include fatigue, skin reactions, and immune-related effects.

Ongoing Clinical Trials on Lbl-007

  • Study of Tislelizumab, Surzebiclimab, and LBL-007 for Patients with Recurrent or Metastatic Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study of BGB-A425, LBL-007, and Tislelizumab for Patients with Advanced Head and Neck Cancer, Lung Cancer, or Kidney Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Poland Spain

  • Study of Tislelizumab, LBL-007, and BGB-15025 in Patients with Advanced Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Romania Spain

Glossary

  • LAG-3: Lymphocyte-activation gene 3, a protein involved in regulating immune responses. LBL-007 targets this protein to potentially enhance the immune system's ability to fight cancer.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer cells.
  • Objective Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Dose-Limiting Toxicity (DLT): Side effects severe enough to prevent giving a higher dose of a treatment.
  • Maximum Tolerated Dose (MTD): The highest dose of a drug that can be given without causing unacceptable side effects.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer treatment works.
  • Neoadjuvant Treatment: Treatment given before the main treatment, usually to shrink a tumor before surgery.

References